Aurobindo Pharma Q1 Results Review - Healthy U.S. Sales, Margins To Further Improve: Prabhudas Lilladher

Prabhudas Lilladher Report

Our FY24/25E earnings per share estimate of Aurobindo Pharma Ltd. stands increased by 7-12% to factor in higher margins.

Aurobindo Pharma’s Q1 FY24 Ebitda of Rs 11.5 billion (up 15% QoQ) with operating profit margin of 16.8% (up 130 basis points QoQ) was 8% above our estimate.

We expect margin trajectory to further improve. Pick up in U.S. sales hinge on timely niche approvals along with stabilization of pricing pressure in base business.

We believe Aurobindo Pharma has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and production linked incentive which are expected to be reflected from FY25.

At current market price, stock is trading at 16 times FY25E price/earning. We value company at 16 times FY25E EPS (13 times earlier) and assign a target price of Rs 900/share (Rs 660 earlier).

Given a sharp 20% appreciation in stock price in less than one month and limited upside, we cut our rating from 'Buy' to 'Accumulate'.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.